You are here: Home » PTI Stories » National » News
Business Standard

Sanofi launches new diabetes treatment insulin in India

Press Trust of India  |  New Delhi 

Drug firm today said it has launched treatment 'Toujeo' in the country.

The product, which is a next generation basal insulin, is a once-daily long-acting basal analog that improves glycemic control in adults with type 1 and type 2

"The launch of Toujeo reaffirms our strong commitment of expanding Sanofi's portfolio and to drive better management in India," Managing said in a statement.

Toujeo was first approved in 2015 in the and since then, it has been approved in over 65 countries.

It is a prescription drug and is available in the newly designed SoloSTAR pen.

Low blood sugar, or is a constant fear amongst people on Toujeo effectively lowers blood glucose, while minimising the risk of hypoglycemia, said.

It works by slowly releasing small amounts of insulin to provide continuous glucose-lowering activity that lasts beyond 24 hours, it added.

shares were trading up 2.27 per cent at Rs 4,828.75 on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, February 12 2018. 14:45 IST